1. Home
  2. EXEL vs NYT Comparison

EXEL vs NYT Comparison

Compare EXEL & NYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$43.63

Market Cap

11.7B

Sector

Health Care

ML Signal

HOLD

Logo New York Times Company (The)

NYT

New York Times Company (The)

HOLD

Current Price

$85.91

Market Cap

11.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXEL
NYT
Founded
1994
1851
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
11.5B
IPO Year
2000
1994

Fundamental Metrics

Financial Performance
Metric
EXEL
NYT
Price
$43.63
$85.91
Analyst Decision
Buy
Buy
Analyst Count
21
6
Target Price
$46.45
$70.17
AVG Volume (30 Days)
2.1M
1.9M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
1.07%
EPS Growth
57.95
18.08
EPS
2.78
2.09
Revenue
$452,477,000.00
$1,783,639,000.00
Revenue This Year
$13.66
$10.40
Revenue Next Year
$13.39
$6.35
P/E Ratio
$15.78
$41.00
Revenue Growth
N/A
N/A
52 Week Low
$32.38
$44.83
52 Week High
$48.74
$86.17

Technical Indicators

Market Signals
Indicator
EXEL
NYT
Relative Strength Index (RSI) 59.68 68.87
Support Level $40.42 $78.49
Resistance Level $45.88 N/A
Average True Range (ATR) 0.95 1.66
MACD 0.33 0.12
Stochastic Oscillator 90.88 93.02

Price Performance

Historical Comparison
EXEL
NYT

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About NYT New York Times Company (The)

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.

Share on Social Networks: